

Relationships With Industry

Name: Shaun Goodman

Last updated: Jun 20, 2023

Company/Companies:	Period of Support	Name of Project	1) A research grant or contract from this Company partially supports my University salary	2) A research grant or contract from this Company partially supports my research projects	3) Educational activities or lectures for this Company generates revenue for the University of Alberta		4) Consulting or other services for this company generates personal income		5) I receive significant personal royalties from this Company	6) I have equity in this Company	Comments
					<\$10K	>\$10K	<\$10K	>\$10K			
Canadian VIGOUR Centre (including support from CSL and Boehringer-Ingelheim)	2010-present	AEGIS-2 (2016-present), EMPACT-MI (2020-present), OCEANIC-AF (2021-present), POSIBIL-6 (2022-present) trials	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Including quarterly stipend directed to the St. Michael's Physician's Association
Duke Clinical Research Institute (including support from Daiichi-Sankyo/American Regent, CSL, and Boehringer-Ingelheim)	2010-present	EMPACT-MI (2021-present) and HEART-FID (2019-2023) trials	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Including National Coordinator and DMC activities
Canadian Heart Research Centre and MD Primer	1996-present	Multiple clinical trials, observational registries, and continuing professional development programs	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Including quarterly stipend directed to the St. Michael's Physician's Association (1996-2022)
New York University	2012-present	ISCHEMIA/ISCHEM	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Heart & Stroke Foundation of Ontario/University of Toronto	2011-2021	Heart & Stroke/University of Toronto Polo Chair, Division of Cardiology, Department of Medicine	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Monthly stipend directed to the St. Michael's Physician's Association (2011-2021)
Mayo Clinic	2012-2020	TAILOR-PCI trial	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Steering Committee Member
HCor	2015-2019	TREAT trial	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Steering Committee Member
AstraZeneca	2015-2019	Canadian ACS Reflective 1	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Principal Investigator
Bayer	2017-2019	CONNECT AF+PCI	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Principal Investigator
Bristol-Myers Squibb/Pfizer	2019-2020	CONNECT AF+PCI II	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Principal Investigator
Bayer	2018-2019	CONNECT CVD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Principal Investigator
Sanofi/Regeneron	2012-2019	ODYSSEY Outcomes trial	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Executive Steering Committee stipend
AstraZeneca	2013-2020	TIGRIS study	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Executive Steering/Publication Committee stipend
Novo-Nordisk	2019-present	SOUL and FLOW trials	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Data Monitoring Committee member
Daiichi-Sankyo/American Regent	2017-2023	HEART-FID trial	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Data Monitoring Committee member
University Court of the University of Edinburgh	2014-present	ACS Risk Working Group Canadian study	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Ferring Pharmaceuticals	2015-2021	PRONOUNCE trial	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Executive Steering Committee member
Bristol-Myers Squibb/Pfizer	2015-2019	AUGUSTUS trial	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Executive Steering Committee member
Bristol-Myers Squibb/Pfizer	2016-2019	OPTIMAL AF	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Principal Investigator
Amgen Pharmaceuticals	2015-2020	GOAL and GOAL-2 registries	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Steering Committee member
Amgen Pharmaceuticals	2019-2020	CV MOBIUS	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Executive Steering Committee member
CSL Behring (through PERFUSE Research Institute)	2016-present	AEGIS-II	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Executive Steering Committee member
Esperson (through Cleveland Clinic Coordinating Center for Clinical Research [C5])	2018-2023	CLEAR OUTCOMES	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Steering Committee member
Boehringer-Ingelheim	2020-present	EMPACT-MI	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Steering Committee member
Bayer	2020-2023	TRANSECT AF	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Principal Investigator
Novartis	2020-2023	HF-IDOC	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Study Chair
Bayer	2021-present	OCEANIC-AF	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Executive Steering Committee member
CSL Behring (through the Duke Clinical Research Institute [DCRI])	2022-present	POSIBIL-6	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Canadian site operations
TIMI Study Group (Brigham Health; through Anthos Therapeutics)	2020-present	AZALEA-TIMI 71 (2020-present) and LILAC (2022-present) trials	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Steering Committee member
CYTE	2022-present	GARDENIA Registry (2022-present)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Steering Committee member
Idorsia	2021-present	SOS-AMI (2021-present)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Steering Committee member
Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Eli Lilly, Ferring Pharmaceuticals, HLS Therapeutics, JAMP Pharma, Merck, Novartis, Pendopharm/Pharmascience, Pfizer, Regeneron, Sanofi, Servier, Valeo Pharma	2016-present	Consulting/Advisory Boards/Rounds/Side development	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Monetary amounts are on an annual basis.

Column Explanation:

- (1) Funding is provided for my effort in research grants/ contracts for multi-center projects in which I serve in an executive function, this often is combined with Canadian operational responsibility. Remuneration for such work is received through the St. Michael's Physicians' Association/Department of Medicine at St. Michael's Hospital and the University of Toronto in Toronto, and Capital Health in Edmonton.
- (2) A research grant from this company or academic research organization supports the expenses associated with projects in the Canadian Heart Research Centre/MD Primer, and the Canadian VIGOUR Centre/University of Alberta where I am a consultant and Co-Director, respectively.
- (3) I provide educational activities or deliver occasional lectures that generate revenue from this company. The two columns represent annual payments of more or less than \$10,000 per year from this company.
- (4) I receive personal income for consulting and speaking engagements/rounds from this company. The two columns represent annual payments of more or less than \$10,000 from this company.